FDA OKs new use of Roche's Xolair

 

• The FDA approves Roche's (OTCQX:RHHBY +1.9%) Xolair (omalizumab) as add-on maintenance treatment of nasal polyps in adults who fail to adequately response to corticosteroids.
• The anti-IgE antibody was first approved in 2003 for asthma in patients at least 12 years old.
• Related ticker: Novartis (NVS -0.4%)
• https://seekingalpha.com/news/3640446-fda-oks-new-use-of-roches-xolair